Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
In Breast Cancer Research : BCR, 2008
... were re-cut and sections were immunostained for ER (SP1 antibody, Neomarkers, Fremont, CA, USA), PR (PgR 636 antibody, Dako, Carpinteria, CA, USA) and ... Relationship between HER2 status and proliferation rate in breast cancer assessed by immunohistochemistry, fluorescence in situ hybridisation and standardised AgNOR analysismore suppliers
In Pathology Research International, 2002
... Dako, Denmark), HER-2/neu (titer 1 : 50, Dako, Denmark), ER (clone 1D5, Dako, Denmark), and PR (clone PgR 636, Dako, Denmark), was performed by ...
Biomarker assessment and molecular testing for prognostication in breast cancer.
Ottawa, Canada. In Histopathology, Jan 2016
Oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) define prognosis and identify tumours for targeted therapy, and remain the sole established single-molecule biomarkers defining the minimum breast cancer pathology data set.
Ulipristal acetate for uterine fibroid-related symptoms.
Paris, France. In Drugs Today (barc), Nov 2015
Ulipristal acetate (UPA) is an orally active synthetic selective progesterone receptor modulator (SPRM) characterized by a tissue-specific progesterone antagonist effect that reduces the proliferation of leiomyoma cells and induces apoptosis.
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity.
More papers using
Brussels, Belgium. In Nature, Oct 2015
Surprisingly, oncogenic Pik3ca(H1047R) mutant expression at physiological levels in basal cells using keratin (K)5-CreER(T2) mice induced the formation of luminal oestrogen receptor (ER)-positive/progesterone receptor (PR)-positive tumours, while its expression in luminal cells using K8-CReER(T2) mice gave rise to luminal ER(+)PR(+) tumours or basal-like ER(-)PR(-) tumours.